Amphotericin B lipid complex in pediatric patients with invasive fungal infections

Pediatric Infectious Disease Journal

Volumn 18, Issue 8, 1999, Pages 702-708

  Walsh, Thomas J ^a   Seibel, Nita L ^b   Arndt, Carola ^c   Harris, Richard E ^d   Dinubile, Mark J ^e   Reboli, Annette ^e   Hiemenz, John ^f   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e Department of Anesthesiology   (United States)

^f Walt Disney Mem Cancer Institute   (United States)

Author keywords

Amphotericin B; Amphotericin B lipid complex; Aspergillosis; Candidiasis; Fusariosis; Zygomycosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; CANDIDIASIS; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC MYCOSIS;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MYCOSES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; ZYGOMYCOSIS;

EID: 0032806739     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199908000-00010     Document Type: Article

References (30)

1. Walsh TJ, Gonzalez C, Lyman CA, Chanock S, Pizzo PA. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1995;11: 187-290.
2. Wiley JM, Smith N, Leventhal B, et al. Invasive fungal disease in pediatric leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280-6.
3. Flynn PM, Marina NM, Rivera GK, Hughes WT. Candida tropicalis infections in children with leukemia. Leuk Lymphoma 1993;10:369-76.
4. Walsh TJ, Gonzalez C, Roilides E, et al. Fungemia in HIV-infected children: new epidemiologic patterns, emerging pathogens, and improved antifungal outcome. Clin Infect Dis 1995;20:900-6.
5. Rowen JL, Correa AG, Sokol DM, Hawkins HK, Levy ML, Edwards MS. Invasive aspergillosis in neonates: report of five cases and literature review. Pediatr Infect Dis J 1992;11:576-82.
6. Shetty D, Giri N, Gonzalez CE, Pizzo, PA, Walsh, TJ. Invasive aspergillosis in HIV-infected children. Pediatr Infect Dis J 1997;16:216-21.
7. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive aspergillosis infection in a pediatric hospital: a ten year review. Pediatr Infect Dis J 1993;12:673-8.
8. Leggiadro R, Barrett F, Hughes W. Extrapulmonary cryptococcosis in immunocompromised infants and children. Pediatr Infect Dis J 1992;11:43-7.
9. Leggiadro R, Kline M, Hughes W. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991;10:658-62.
10. Gonzalez C, Shetty D, Lewis L, Mueller B, Pizzo PA, Walsh TJ. Cryptococcosis in HIV-infected children. Pediatr Infect Dis J 1996;15:796-800.
11. Fisher DJ, Christy C, Spafford P, Maniscalco WM, Hardy DJ, Graman PS. Neonatal Trichosporon beigelii infection: report of a cluster of cases in a neonatal intensive care unit. Pediatr Infect Dis J 1993;12:149-55.
12. Boutati EI, Anaissie EJ. Fusarium: a significant emerging pathogen: new implications for management in patients with hematological cancer. Blood 1997;90:999-1008.
13. Sarosi GA. Amphotericin B: still the "gold standard" for antifungal therapy. Postgrad Med 1990;88:151-66.
14. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
15. Maddux MS, Barrier SL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1990;14:177-81.
16. Miller RP, Bates JH. Amphotericin B toxicity: a follow-up report of 53 patients. Ann Intern Med 1969;71:1089-95.
17. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 1990;5:94-108.
18. Hiemenz, JW, Walsh, TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22:S133-44.
19. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6.
20. Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451-71.
21. Perkins WR, Minchey SR, Boni LT, et al. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992;1107:271-82.
22. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-21.
23. Allendoerfer R, Yates RR, Sun SH, Graybill JR. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992;30:377-84.
24. Mitsutake K, Kohno S, Miyazaki, et al. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 1994;128:13-7.
25. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994;33:73-81.
26. Swenson CE, Janoff AS. Preclinical studies with amphotericin B lipid complex. Drugs Today 1996;32:397-402.
27. Anaissie EJ, White M, Uzun O, et al. Poster session: amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial [Abstract LM 1995]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995:330.
28. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26: 1383-96.
29. Patterson TS, Barton LL, Shehab ZM, Hutter JJ. Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Clin Pediatr 1996; 35:257-60.
30. Walsh TJ, Whitcomb T, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-8.